课题基金 / 基金详情

Development of an immune complex vaccine to control variant infectious bursal disease virus (IBDV) infections in the broiler chicken industry in Canada

Development of an immune complex vaccine to control variant infectious bursal disease virus (IBDV) infections in the broiler chicken industry in Canada
开发免疫复合物疫苗来控制加拿大肉鸡行业的变异传染性法氏囊病病毒 (IBDV) 感染
批准号:
506071-2016
负责人:
Gomis, Susantha
金额:
$5.18万
依托单位:
依托单位国家:
加拿大
项目类别:
Collaborative Research and Development Grants
财政年份:
2017
资助国家:
加拿大
项目状态:
已结题
起止时间:
2017-01-01 至 2018-12-31

项目摘要

项目成果

Gomis, Susantha的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Infectious bursal disease virus (IBDV) was first recognized in the USA near the town of Gumboro, Delaware (Gumboro disease). Infectious bursal disease virus belongs to the genus Avibirnavirus of the family Birnaviridae and causes infectious bursal disease (IBD), an acute highly contagious disease of 3- to 6-week-old chickens. The most severe consequence of IBDV infection is the functional loss of the bursa of Fabricius. IBD is one of the most important avian acquired immunosuppressive diseases and has led to large losses to the poultry industry worldwide. IBDVs emerged that could not be controlled by immunization with vaccines prepared from ''classic'' IBDV strains, and were called variants IBDVs (vIBDVs). The control of IBD in Canada has been complicated by the recognition of vIBDVs. Our previous research has identified 43% of broiler flocks or premises (or 52% of barns) in Saskatchewan are infected with vIBDV. It is apparent that flocks with vIBDV infection have a poor feed conversion ratio, high mortality, bursal atrophy and decreased meat production. This has led to an annual loss of over 3.9 million kilograms of broiler production per year in the Saskatchewan broiler chicken industry. This mass of chicken meat lost had a wholesale market value of over $13 million per year. Moreover, in recent years, increased condemnations of broiler carcasses due to bacterial hepatitis was recognized due to immunosuppression. Our research has demonstrated that current vaccination programs against IBDV in the broiler breeder industry in Canada are not effective in controlling vIBDV because of antigenic differences between US-sourced vaccines and vIBDVs circulating in the broiler chicken industry in Canada. Furthermore, we have discovered that current vaccines used in the broiler chicken industry are not able to provide protection against the Canadian vIBDV. Recently, our research revealed an unrecognized phenomenon that the immunization of broilers with vectored vaccine induces immunosuppression that may further increase susceptibility to vIBDV infection. Because of these reasons, we are proposing to develop a IBDV vaccine using Canadian isolates to control vIBDV in the broiler chicken industry in Canada.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Oligodeoxynucleotides containing CpG motifs (CpG-ODN) as an innate immune stimulator in broiler chickens
  • 批准号:
    RGPIN-2018-06502
  • 项目类别:
    Discovery Grants Program - Individual
  • 资助金额:
    $6.12万
  • 财政年份:
    2022
  • 负责人:
    Gomis, Susantha
  • 依托单位:
Metabolomics-based rapid disease diagnostic and performance testing kit development for broiler chickens
  • 批准号:
    560280-2020
  • 项目类别:
    Alliance Grants
  • 资助金额:
    $6.47万
  • 财政年份:
    2021
  • 负责人:
    Gomis, Susantha
  • 依托单位:
Oligodeoxynucleotides containing CpG motifs (CpG-ODN) as an innate immune stimulator in broiler chickens
  • 批准号:
    RGPIN-2018-06502
  • 项目类别:
    Discovery Grants Program - Individual
  • 资助金额:
    $3.06万
  • 财政年份:
    2021
  • 负责人:
    Gomis, Susantha
  • 依托单位:
Metabolomics-based rapid disease diagnostic and performance testing kit development for broiler chickens
  • 批准号:
    560280-2020
  • 项目类别:
    Alliance Grants
  • 资助金额:
    $6.47万
  • 财政年份:
    2020
  • 负责人:
    Gomis, Susantha
  • 依托单位:
国内基金
海外基金
声致离子电流促进小胶质细胞M2极化阻断再生神经瘢痕退变免疫机制
  • 批准号:
    82371973
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    孙迪
  • 依托单位:
转运蛋白RCP调控巨噬细胞脂肪酸氧化参与系统性红斑狼疮发病的机制研究
  • 批准号:
    82371798
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    叶俊娜
  • 依托单位:
基于FCER1G基因介导免疫反应探讨迟发性聋与认知障碍相关性的机制研究
  • 批准号:
    82371141
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    陈颖
  • 依托单位:
CD27-CD28-CD8+T细胞调控儿童肝脏移植免疫耐受形成的作用和机制
  • 批准号:
    82371791
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    刘永波
  • 依托单位: